NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair

December 19, 2024

Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, especially with immunotherapy in the neoadjuvant and definitive setting for mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced or metastatic rectal cancer. As immunotherapy continues to be brought to the forefront of rectal cancer, care teams must be equipped to manage toxicities and provide appropriate supportive care recommendations during a patient’s treatment course.

Target Audience

This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the prevalence of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) in rectal cancer.
  • Illustrate the role of neoadjuvant immunotherapy for the treatment of locally advanced or metastatic rectal cancer.
  • Discuss key patient counseling and monitoring considerations for neoadjuvant immunotherapy in locally advanced setting for rectal cancer.

You may also be interested in

NCCN Guidelines® Insights - Rectal Cancer, Version 3.2024
These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Updates in the Management of Locally Advanced Rectal Cancer
The management of locally advanced rectal cancer is rapidly changing based on new data from several clinical trials on the topic. Some of the important updates have involved new treatment options for dMMR/MSI-H rectal cancers and selective usage of radiation or surgery, based on reassessment of response during perioperative therapy.
Team-Based Case Review: Colorectal Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Additional information
Supporters: 

This activity is supported by educational grants from GSK and Menarini-Stemline. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
10/10/2024
Course expires: 
03/09/2025
Event starts: 
12/19/2024 - 12:00pm EST
Event ends: 
12/19/2024 - 1:00pm EST
Cost:
$0.00
Part of: 
NCCN 2024 Pharmacy Updates: A Webinar Series
Add to calendar: 

Elizabeth Dow-Hillgartner, PharmD, BCOP
University of Wisconsin Carbone Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.

Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau 

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-117-L01-P

Physician Associates/Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Thursday, December 19, 2024, from 12:00 – 1:00 PM EST (UTC -5).
The recorded activity is available here.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing